Novartis reports mixed first-quarter results as sales and profitability decline

7 articles · Updated · The Wall Street Journal · Apr 28

Novartis sales fell 1% in U.S. dollars, missing expectations, and shares dropped 4.2% to 109.28 Swiss francs.
Profitability decreased more than anticipated, mainly due to generic erosion of three key drugs, but the company maintained its full-year guidance.
Novartis expects second-quarter sales to decline further, with growth anticipated in the second half of 2026 despite current market pressures.

With its blockbuster drug facing a patent cliff, can Sanofi's M&A strategy rebuild its pipeline fast enough?

As Novartis faces lawsuits over its Sandoz spin-off, what precedent does this set for corporate accountability?

Can AstraZeneca maintain its growth while relying heavily on its partner's manufacturing network?

How will Trump's new pricing policy reshape global pharmaceutical innovation and investment?

Will new competitors in eye care dethrone Roche's Vabysmo and lower costs for patients?

Beyond extending patents, what are the most effective strategies for pharma giants to manage drug lifecycles?